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QUESTIONS
1. What is GvHD?
2. How does UVR affect GvHD?
3. How did the investigators carry out their study, and what were the results?
4. What were the conclusions and implications of the study?
For answers, visit our website or scan the adjacent tag.
Although the mechanisms of graft-versus-host disease (GvHD) continue 
to be elucidated, it is clear that acute GvHD (aGvHD) causes significant 
morbidity and mortality. Because antigen-presenting cells, including 
Langerhans cells (LCs), are important for the initiation of GvHD in animals, 
reduction of the donor LC population in patients receiving allogeneic 
hematopoietic cell transplantation (HCT) has been hypothesized to 
improve outcomes (Merad et al., 2004). Although UV radiation (UVR) 
is one method for reducing LC numbers in the skin, a previous study of 
adjuvant UVR in combination with standard pharmaceutical therapies 
demonstrated poorer outcomes in the transplant patients than in patients 
treated with standard therapies alone (Yuksel et al., 2006).
To explore the use of UVR for preventing GvHD, Kreutz et al. (2012, 
this issue) tested a novel protocol that involved delivery of broadband UVR using spectrum B (UVB) after trans-
plant every other day for 6 treatments because the type and timing of UVR are probably important for its efficacy. 
Seventeen patients with a variety of hematologic malignancies were treated with UVB after initial conditioning and 
transplantation. The timing and severity of aGvHD were documented, and baseline and follow-up skin biopsy spec-
imens were evaluated. A cohort of similar patients who had hematologic malignancies and were treated with initial 
conditioning and transplant ation without UVB served as a control.
In contrast to the previous studies, Kreutz et al. (2012) found that UVB was tolerated. Additionally, successful and 
complete depletion of CD1a+ LCs was observed in more than half of the patients. None of the patients with com-
plete depletion of LCs developed a grade II or greater aGvHD reaction, whereas 5 of 8 patients with incomplete LC 
depletion developed grade II or greater aGvHD. The control cohort did not fare as well. Although LC depletion was 
measured, other mechanisms, such as increased regulatory T cells and higher vitamin D levels, may also be at play 
in this success. Development of aGvHD decreased with UVB treatment; however, no effect on chronic GvHD was 
observed.
Through the following questions, we examine this paper in greater detail. For brief answers, please refer to the 
supplementary information online <http://www.nature.com/jid/journal/v132/n1/suppinfo/jid2011396s1.html>.
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